More about
Tp53-Mutated Cancer
News
December 02, 2022
2 min read
Save
Eprenetapopt regimen beneficial after HSCT for TP53-mutant AML, myelodysplastic syndrome
Maintenance therapy with eprenetapopt plus azacitidine after hematopoietic stem cell transplantation led to improved survival outcomes among patients with TP53-mutant acute myeloid leukemia or myelodysplastic syndrome, study results showed.